Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials by unknown
Zhu et al. BMC Urology  (2015) 15:47 
DOI 10.1186/s12894-015-0043-4RESEARCH ARTICLE Open AccessImpact of preoperative 5α-reductase inhibitors
on perioperative blood loss in patients with
benign prostatic hyperplasia: a meta-analysis of
randomized controlled trials
Yi-Ping Zhu1,2, Bo Dai1,2, Hai-Liang Zhang1,2, Guo-hai Shi1,2 and Ding-Wei Ye1,2*Abstract
Background: The ability of 5α-reductase inhibitors (5ARIs) to decrease blood loss during transurethral resection of
the prostate (TURP) for benign prostatic hyperplasia (BPH) remains controversial. We aimed to conduct a meta-analysis
of all randomized controlled trials (RCTs) to establish the role of 5ARI use prior to TURP.
Methods: We searched studies from the electronic databases PubMed, Embase, Scopus, and Cochrane Library from
inception to March 25, 2014. Meta-analysis was performed using the statistical software Review Manager version 5.1.
Results: Seventeen RCTs including 1489 patients were examined. We observed that preoperative treatment with
finasteride can decrease total blood loss, blood loss per gram of resected prostate tissue, hemoglobin level alteration,
microvessel density (MVD), and vascular endothelial growth factor level. Neither finasteride nor dutasteride reduced
operative time, prostate volume, or the weight of gland resected. In contrast, pretreatment with dutasteride before
TURP did not decrease the total blood loss or MVD.
Conclusions: Pretreatment with finasteride does seem to reduce perioperative blood loss related to TURP for BPH
patients. However, the effect of preoperative dutasteride was inconclusive. Further studies are required to strengthen
future recommendations regarding the use of 5ARI as a standard pre-TURP treatment and its optimal regimen.
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Transurethral resection of the prostate (TURP) remains
the gold standard for patients with benign prostatic
hyperplasia (BPH) that failed medical therapy. Periopera-
tive hemorrhage is one of the major complications of
TURP, and prolonged bleeding will lead to blood trans-
fusion and clot retention [1]. 5α-Reductase inhibitors
(5ARIs), including finasteride and dutasteride, can block
the conversion of testosterone to dihydrotestosterone
(DHT) and has been used to treat BPH and BPH-related
hematuria [2].* Correspondence: dwye.tumor@gmail.com
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unless otherwise stated.Since Hagerty et al. [3] first reported that pretreatment
with finasteride appears useful in reducing perioperative
bleeding in patients undergoing TURP, emerging studies
have reported similar results [4–18]. However, the ability
of 5ARI to decrease blood loss during TURP for BPH re-
mains controversial, and several studies have reported
no significant benefit of preoperative 5ARIs [19–21].
One systematic review also demonstrated that preopera-
tive finasteride can reduce blood loss during TURP while
dutasteride cannot [22]. However, the systematic review
was criticized for including a nonrandomized trial [23]
and a study comparing photoselective vaporization of
the prostate (PVP) instead of TURP with controls [24].
Therefore, we aimed to conduct a meta-analysis of all
randomized controlled trials (RCTs) to establish the role
of 5ARI use prior to TURP.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data sources and search strategy
The present meta-analysis was conducted following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [25].No protocol
exists for this meta-analysis. We searched studies from
the electronic databases PubMed, Embase, Scopus, and
Cochrane Library from inception to March25, 2014.The
search terms used were 5α-reductase inhibitor, TURP,
transurethral resection of the prostate, 5ARI, BPH,
dutasteride, and finasteride. Meanwhile, references from
all retrieved papers were manually searched for further
relevant articles. We also searched for abstracts of ran-
domized trials from conference proceedings. If the re-
sults of the same population were reported more than
one time, only the most recent and complete data were
included. No language or other restrictions were used in
the search.
Study selection
Studies were considered eligible if they met the following
criteria: (1) the study was a RCT, (2) the study partici-
pants were BPH patients undergoing monopolar TURP,
(3) the main exposure of interest was use of 5ARI in the
preoperative period, and (4) the study reported at least
one of the following: estimated blood loss(EBL), decrease
in hemoglobin (Hb) level, resection weight, blood loss
per gram of resected tissue, microvessel density (MVD),
and vascular endothelial growth factor (VEGF) level.
We excluded studies if(1) the study was nonrandomized,
(2)the full text of the study could not be accessed, (3)out-
comes relevant to our interests were not reported, (4) we
could not extract data in the appropriate format and failed
to obtain the data from the authors, or (5) interventions
were bipolar TURP, PVP, or holmium laser enucleation of
the prostate (excluded because only one study using PVP
and one study using bipolar TURP used 5ARI in the pre-
operative period, indicating that we could not pool the
data into a meta-analysis and perform subgroup analysis
because the sample size was too small).
Data extraction and risk of bias assessment
Data were independently extracted from each study
applying a standardized form by two reviewers and then
cross-checked. Any disagreement was resolved by dis-
cussion between the two authors. If these two authors
could not reach a consensus, another author was con-
sulted to resolve the dispute and a final decision was
made by a majority vote. The quality of the included
RCTs was assessed by the Cochrane Risk of Bias Tool.
Data synthesis and analysis
We used the mean difference (MD) and relative risk
with a 95% confidence interval (CI) for continuous anddichotomous data, respectively. For studies that pre-
sented continuous data as median and range values, the
means and standard deviations were calculated using
statistical algorithms described by Hozo et al. [26].The
DerSimonian and Laird random-effects model was used
if there was evidence of heterogeneity between the stud-
ies, based on the χ2 test for heterogeneity and the I2 test.
A P value <0.10 and an I2 value >50%, respectively, were
considered high [27]. Otherwise, the fixed-effect model
(Mantel-Haenszel) was selected. Publication bias was
assessed using inverted funnel plots. Sensitivity analysis
was performed to examine whether the effect estimate
was robust to exclusion of different criteria. Analysis




Figure 1 traces the flow of our literature search. Briefly,
we retrieved 21 potentially relevant studies for quality
evaluation and excluded four RCTs [12, 24, 28, 29] for
different reasons. One publication [28] was excluded
because it was written in Italian, and we could not con-
tact the author for the English version. Two publica-
tions were excluded because the interventions were
PVP [24] or transurethral plasmakinetic enucleation of
prostate [29]. Two publications by Donohue et al. [8,
12] had overlapping populations, and one study was
excluded from meta-analysis because it reported a
lower number of cases than the one we included [8].
Finally, 17 RCTs [4–11, 13–21] including 1489 patients
met the inclusion criteria (746 with 5ARI and 743
without). The characteristics of included RCTs are
summarized in Table 1.
Risk of bias assessment
The results of the risk of bias assessments are reported
in Table 2. Overall, most studies had moderate to high
risk of bias. The method of randomization was clearly
depicted in only three trials. Allocation concealment was
adequately stated in six trials. Blinding was evaluated
separately for patients and outcome assessors. Blinding
of outcome assessment was part of the trial design in




Nine RCTs including 729 patients evaluated EBL be-
tween a 5ARI group and a control group (including
seven RCTs for finasteride and two RCTs for dutaste-
ride). Pooling data showed a significant benefit of 5ARI
on reducing EBL in the finasteride group, whereas no
conspicuous difference was observed in the dutasteride
Fig. 1 PRISMA flow diagram. PV: Photoselective vaporization of the prostate; RCT: Randomized controlled trial; TUPKEP: Transurethral plasmakinetic
enucleation of prostate
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there was evidence of significant heterogeneity (Fig. 2).
Blood loss per gram of resected prostate tissue
Five RCTs that included 323 patients evaluated blood
loss per gram of resected prostate tissue between 5ARI
and control groups (including four RCTs for finasteride
and one RCT for dutasteride). Pooling data showed a
significant benefit of 5ARI on reducing blood loss per
gram of resected prostate tissue in both the finasteride
and dutasteride groups. The random-effects model was
reported because there was evidence of significant het-
erogeneity (Fig. 3).
Hb alteration
Five RCTs including 452patients reported Hb change
before and after TURP (including two RCTs for finaste-
ride and three RCTs for dutasteride). When pooled, the
results showed that 5ARI reduced the Hb change in the
finasteride group but not in the dutasteride group. The
random-effects model was selected because there was
evidence of significant heterogeneity (Fig. 4).
Blood transfusions needed
Eight RCTs including 565 cases evaluated patients
who needed a blood transfusion (including four RCTs
for finasteride and four RCTs for dutasteride). When
pooled, although there was a trend in favor of the 5ARIgroup, the result did not show significant differences
between treatment and control groups (P = 0.05). Ac-
cording to our analysis, no heterogeneity was found
among the trials (I2 = 0); thus, a fixed-effects model was
chosen for the analysis (Fig. 5).
MVD and VEGF expression after 5ARI treatment
To elucidate the mechanism of 5ARI action, we identi-
fied eight RCTs that evaluated MVD (including six RCTs
for finasteride and two RCTs for dutasteride), and six
RCTs evaluated VEGF expression after 5ARI treatment
(six RCTs including 746 patients for finasteride).The
overall result of the meta-analysis showed that the MVD
and VEGF of the resected prostate tissue were lower in
the finasteride group than in the control group, whereas
oral dutasteride did not decrease MVD. The random-
effects model was reported because there was evidence
of significant heterogeneity (Figs. 6 and 7).
Other parameters
We also evaluated other parameters between the 5ARI
and control groups in the present meta-analysis, including
operative time, weight of gland resected, and prostate
volume. The pooled data showed that both finasteride
and dutasteride did not reduce operative time, prostate
volume, or weight of gland resected. On the contrary,
lesser gland tissue was resected and the prostate volume
was smaller in the control group (Table 3).
Table 1 Study characteristics
Study Country Age Sample size Intervention Dose and duration Outcomes evaluated
5ARI Control 5ARI Control 5ARI Control
Sandfeldt 2001 [10] Sweden 69 68 26 29 Fin placebo 5mg daily, 12 weeks blood loss, operating time, resection weight, MVD
HäggstrÖm 2002 [13] Sweden NM NM 15 13 Fin placebo 5mg daily, 12 weeks VEGF, MVD
Donohue 2002 [8] UK 69.9 70.2 32 36 Fin placebo 5mg daily, 2 weeks blood loss, resection weight
Liu 2003 [14] China 68.9 68.4 50 50 Fin blank 5mg daily, 2 weeks blood loss, Hb alteration, operating time, resection
weight, MVD, VEGF
Li 2004 [6] China 70.7 72.1 40 40 Fin blank 5mg daily, 1–2 weeks blood loss, operating time, resection weigh
Özdal 2005 [4] Turkey 66.9 66.3 20 20 Fin blank 5mg daily, 4 weeks blood loss, Hb alteration, resection weight
Lund 2005 [19] Denmark 66.5 67 16 17 Fin placebo 5mg daily, 12 weeks blood loss, operating time, resection weight
Boccon 2005 [16] France NM NM 32 27 Dut placebo 0.5mg daily,4 weeks Hb alteration, resection weight
Lekas 2006 [7] Greece 68.6 68.8 88 90 Fin blank 5mg daily, 25.3 weeks blood loss, MVD ,VEGF
Hahn 2007 [20] multicenter
3-arm study
67/67 66 72/71 70 Dut placebo 0.5mg daily, 4 weeks
before and 2 weeks
after TURP
Hb alteration per gramprostate; MVD
Memis 2008 [11] Turkey 65 64 13 17 Fin blank 5mg daily, 4 weeks MVD
Berardinis 2008 [9] Italy 68 69 100 100 Fin placebo 5mg twice, 8 weeks MVD,VEGF
Tuncel 2009 [21] Turkey 68.1 67.7 27 21 Dut blank 0.5mg daily,5 weeks Blood loss, Hb alteration, MVD
Kravchick 2009 [17] Israel 67.7 66.15 24 22 Dut blank 0.5mg daily,6 weeks blood loss, operating time, resection weight
He 2012 [15] China 64.5 65.5 30 30 Fin blank 5mg daily, 2 weeks blood loss, operating time, resection weight, MVD ,VEGF
Pastore 2013 [18] Italy 65.66 66.7 71 71 Dut blank 0.5mg daily,6 weeks blood loss, operating time, resection weight
Liu 2013 [14] China 69.2 68.4 90 90 Fin blank 10mg twice, 2 weeks blood loss, operating time, resection weight, VEGF



























Sandfeldt 2001 [10] Unclear risk low risk low risk low risk low risk low risk low risk
HäggstrÖm 2002 [13] Unclear risk Unclear risk high risk high risk low risk low risk low risk
Donohue 2002 [8] Unclear risk Unclear risk low risk Unclear risk low risk low risk low risk
Liu 2003 [5] Unclear risk Unclear risk high risk high risk high risk low risk low risk
Li 2004 [6] Unclear risk Unclear risk high risk high risk high risk low risk low risk
Özdal 2005 [4] Unclear risk Unclear risk low risk Unclear risk low risk low risk low risk
Lund 2005 [19] low risk low risk Unclear risk Unclear risk low risk low risk low risk
Boccon 2005 [16] Unclear risk low risk low risk low risk low risk low risk low risk
Lekas 2006 [7] low risk Unclear risk high risk high risk low risk low risk low risk
Hahn 2007 [20] Unclear risk low risk low risk low risk low risk low risk low risk
Memis 2008 [11] Unclear risk Unclear risk high risk high risk low risk low risk low risk
Berardinis 2008 [9] Unclear risk low risk low risk low risk low risk low risk low risk
Tuncel 2009 [21] Unclear risk Unclear risk high risk high risk high risk low risk low risk
Kravchick 2009 [17] high risk low risk high risk high risk high risk low risk low risk
He 2012 Unclear risk Unclear risk high risk high risk high risk low risk low risk
Pastore 2013 low risk Unclear risk low risk Unclear risk low risk low risk low risk
Liu 2013 [14] Unclear risk Unclear risk high risk high risk low risk low risk low risk













Fig. 2 Forest plot presenting the meta-analysis for the effect of 5ARI treatment on blood loss. Pretreatment with finasteride significantly
reduced perioperative blood loss (P < 0.00001) while dutasteride did not (P = 0.24). 5ARI: 5α-Reductase inhibitors; CI: Confidence interval;
Dut: Dutasteride; Fin:Finasteride
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Sensitivity analysis was performed by sequential re-
moval of individual studies and cumulative statistics for
all comparisons of all subjects. The pooled MD was not
influenced by the result of any individual study. Funnel
plots were used to assess the publication bias. All stud-
ies lie inside the 95% CIs, with an even distribution
around the vertical, indicating no obvious publication
bias (Fig. 8).Fig. 3 Forest plot presenting the effect of 5ARI treatment on blood loss peDiscussion
5ARI is commonly used for treating BPH and hematuria
of prostatic origin. However, the concept of preopera-
tively administering 5ARI to reduce blood loss during
TURP has not been accepted by most urologists. In a
United Kingdom-based survey, although 98% of urolo-
gists used finasteride for hematuria of prostatic origin,
only 4% used it before TURP [30]. In the present meta-
analysis involving 17 RCTs and 1489 participants, wer gram of resected prostate tissue
Fig. 4 Forest plot presenting the effect of 5ARI treatment on Hb change before and after TURP
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for 2 weeks to 6 months could decrease blood loss during
TURP for BPH. In contrast, pretreatment with dutasteride
before TURP did not change the total blood loss.
Testosterone is a stimulator of VEGF, and androgen
deprivation leads to decreased blood flow in the prostate
[31, 32]. Finasteride blocks the conversion of testosterone
to DHT, resulting in decreased activity of the androgen-Fig. 5 Forest plot presenting the effect of 5ARI treatment on Blood transfucontrolled growth factors, such as VEGF. MVD is another
histologic indicator of angiogenesis in BPH patients.
Emerging data have shown that finasteride treatment
prior to TURP significantly decreased MVD in the pros-
tate tissue [9–13]. Our meta-analysis confirmed the re-
sults of previous studies, demonstrating that finasteride
could significantly decrease MVD and VEGF of the
prostate tissue compared with controls.sion needed
Fig. 6 Forest plot presenting the effect of 5ARI treatment on MVD
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crease the size of the prostate, and therefore the opera-
tive time might also be decreased secondary to the
smaller gland. However, the present meta-analysis
showed that neither finasteride nor dutasteride prior to
TURP reduced operative time, prostate volume, or
weight of the gland resected. One possible explanation
is that a decrease in the size of the prostate gland re-
quires up to 6 months of finasteride to occur [33].
However, most RCTs in our meta-analysis used finaste-
ride ranging from 2 to 12 weeks, not enough for
shrinkage of the prostate gland. On the contrary, theFig. 7 Forest plot presenting the effect of 5ARI treatment on VEGFeffect of finasteride on hematuria was more rapid than
may reasonably be attributed to decreased prostate size.
Liu et al. [5] showed that MVD and VEGF decreased
obviously in patients treated with finasteride for 14
days. Taken together, the mechanism by which finaste-
ride decreased blood loss during TURP was probably
related to decreased vascularity in the prostate rather
than to a smaller prostate and shorter operative time.
Dutasteride, a dual 5ARI, provides greater suppression
of 5α-reductase because it antagonizes both type I and
II receptors [34]. In theory, it should produce an effect
that is better than, or at least similar to, finasteride.
Table 3 Study outcomes comparing 5ARI with control
Outcomes No of studies (Fin/Dut) No. of patients RR/MD (Total) 95%CI (Total) P value (Fin/Dut/Total) Heterogeneity (Total)
5ARI(Fin/Dut) Control(Fin/Dut) chi2 df I2% P value
Blood loss 7/2 272/94 276/87 −73.04 −107.68,-38.41 <0.00001/0.24/<0.0001 18.31 8 56 0.27
Hb alteration 2/3 52/170 56/174 −0.35 −0.79,0.08 0.04/0.76/0.11 28.12 4 86 <0.0001
Blood loss/g tissue 4/1 136/27 139/21 −3.67 −5.99,-1.36 0.008/0.004/0.002 27.97 4 86 <0.0001
MVD 6/2 296/94 300/87 −5.46 −7.83,-3.09 <0.00001/0.08/<0.00001 675.11 7 99 <0.00001
VEGF 6/0 373/0 373/0 −67.18 −89.78,-44.58 <0.00001 499.53 5 99 <0.00001
Operative time 6/4 252/189 256/180 −3.96 −8.17,2.87 0.12/0.35/0.07 32.46 9 72 0.0002
Transfusion needed 4/4 94/189 102/180 0.37 0.13,1.02 0.17/0.18/0.05 0.99 6 0 0.99
Gland resected 7/4 254/189 262/180 1.09 0.3,1.87 0.01a/0.4/0.006 8.46 10 0 0.58












Fig. 8 Funnel plot of the studies represented in our meta-analysis. This funnel plot provided us with a qualitative estimation of publication bias
of the studies, and no evidence of bias was found. Dut: Dutasteride; Fin:Finasteride
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ferences between the dutasteride and control groups
with regard to EBL, decrease in Hb, resection weight,
prostate volume, transfusions needed, and operative
time. Only one RCT with limited cases showed that pre-
treatment with dutasteride could decrease blood loss
per gram of resected tissue [21].To our surprise, unlike
finasteride, pooling data of two RCTs including 181
cases showed that dutasteride treatment did not de-
crease MVD, which might partially explain why dutaste-
ride was not effective in reducing EBL. In addition,
because dutasteride is a newer drug, the patient popula-
tions recruited to these RCTs were certainly different
from the cohorts that were available for the finasteride
RCTs. Thus, selection bias maybe another plausible ex-
planation for the failure to find a difference in the
dutasteride group. The exact reason dutasteride was not
effective in reducing EBL and MVD remains unclear,
and additional well-designed RCTs are needed to estab-
lish its actual role.
Because approximately 50% of the variability in blood
loss can be accounted for by the amount of resected tis-
sue in TURP, the resection weight and/or prostate size
should be taken into account when calculating EBL [35].
In one study by Sandfeldt et al. [10], a positive correl-
ation between EBL and resection weight was reported.
According to Hagerty et al. [3], patients with resected
weights of >30 g who received finasteride before TURP
needed fewer blood transfusions than those who did not
receive the drug. Although we found no differences
between 5ARI and control groups with regard to trans-
fusions needed, it may be that the trial sample sizes were
not large enough to generate enough data for detectingsignificant effects. In addition, most RCTs in our meta-
analysis did not perform subgroup analysis based on resec-
tion weight (e.g.,>30g) or prostate size. Further studies are
required to fully assess the hypothesis that the benefit of
5ARI treatment would manifest at resected weights of >30
or >40 g or set a cutoff value for prostate size.
The present meta-analysis had some limitations. First
was the quality of the studies assessed; most of the in-
cluded RCTs did not describe randomization concealment
and blinding techniques. Second was the substantial het-
erogeneity among studies, which was probably caused by
the variability among oral 5ARI regimens and outcome
measurements. Oral 5ARI regimens were not standard-
ized, and the studies varied in the dose of 5ARI used as
well as the drug duration and frequency. Data were
therefore analyzed using a random-effects model, which
accounts for both within-study and between-study vari-
ability. Finally, inherent in any meta-analysis is the possi-
bility of publication bias; that is, small studies with null
results tend not to be published. However, several RCTs
included in the meta-analysis also contained negative re-
sults [11, 19–21], and the funnel plot did not provide any
evidence of publication bias.
Conclusion
Pretreatment with finasteride does seem to reduce peri-
operative blood loss related to TURP for BPH patients.
This effect was probably due to decreased vascularity in the
prostate rather than a smaller prostate or shorter operative
time. However, the effect of preoperative dutasteride was
inconclusive. Further studies are required to strengthen
future recommendations regarding the use of 5ARI as a
standard pre-TURP treatment and its optimal regimen.
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